Value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer Journal Article
| Authors: | Morris, P. G.; Ulaner, G. A.; Eaton, A.; Fazio, M.; Jhaveri, K.; Patil, S.; Evangelista, L.; Park, J.; Serna-Tamayo, C.; Howard, J.; Larson, S.; Hudis, C. A.; Mcarthur, H. L.; Jochelson, M. S. |
| Article Title: | Value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer |
| Abstract: | Background: In this retrospective, single-institution study, the authors examine the maximum standardized uptake value (SUVmax) on positron emission tomography/computed tomography (PET/CT) images as a prognostic variable in patients with newly diagnosed metastatic breast cancer (MBC). Methods: Patients with ≥1 metastatic lesion on PET/CT images that were obtained within 60 days of their MBC diagnosis between January 1, 2001 and December 31, 2008 were included. Patients were excluded if they had received chemotherapy ≤30 days before the PET/CT images were obtained. Electronic medical reports were reviewed to determine the SUVmax and overall survival. Because of intraindividual variation in the SUV by body site, separate analyses were conducted by metastatic site. Relationships between site-specific PET/CT variable tertiles and overall survival were assessed using Cox regression; hazard ratios for the highest tertile versus the lowest tertile were reported. Results: In total, 253 patients were identified, and their median age was 57 years (range, 27-90 years). Of these, 152 patients (60%) died, and the median follow-up was 40 months. On univariate analysis, SUVmax tertile was strongly associated with overall survival in patients who had bone metastases (N = 141; hazard ratio, 3.13; 95% confidence interval, 1.79-5.48; P <.001). This effect was maintained on multivariate analysis (HR = 3.19; 95% confidence interval, 1.64-6.20, P =.002) after correcting for known prognostic variables. A greater risk of death was associated with SUVmax tertile in patients who had metastases to the liver (N = 46; hazard ratio, 2.07; 95% confidence interval, 0.90-4.76), lymph nodes (N = 149; hazard ratio, 1.1; 95% confidence interval, 0.69-1.88), and lung (N = 62; hazard ratio, 2.2; 95% confidence interval, 0.97-4.95), although these results were not significant (P =.18, P =.31, and P =.095, respectively). Conclusions: The current results indicate that PET/CT has value as a prognostic tool in patients with newly diagnosed MBC to bone. © 2012 American Cancer Society. |
| Keywords: | adult; cancer chemotherapy; aged; aged, 80 and over; bone neoplasms; middle aged; bone tumor; retrospective studies; major clinical study; overall survival; mortality; review; liver neoplasms; bone metastasis; follow up; lymph node metastasis; lymphatic metastasis; radiopharmaceuticals; disease association; metastasis; lung neoplasms; pathology; breast neoplasms; medical record review; retrospective study; patient identification; lung tumor; electronic medical record; liver metastasis; lung metastasis; diagnostic agent; breast tumor; liver tumor; fluorodeoxyglucose f 18; computer assisted emission tomography; fluorodeoxyglucose f18; neoplasm metastasis; radiopharmaceutical agent; scintiscanning; breast metastasis; metastatic breast cancer; maximum standardized uptake value; cancer prognosis; positron-emission tomography and computed tomography; positron emission tomography/computed tomography; contrast radiography |
| Journal Title: | Cancer |
| Volume: | 118 |
| Issue: | 22 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2012-11-15 |
| Start Page: | 5454 |
| End Page: | 5462 |
| Language: | English |
| DOI: | 10.1002/cncr.27579 |
| PROVIDER: | scopus |
| PUBMED: | 22517371 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 3 December 2012" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work